Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Lupin and Mylan announce Positive European Medicines Agency opinion recommending approval of Nepexto®, Biosimilar Etanercept

Posted On: 2020-03-27 21:41:04


Lupin Limited (Lupin) and Mylan N.V. (NASDAQ: MYL) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Nepexto®, a biosimilar to Enbrel® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.

The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product. In addition, a phase 3 clinical studyi in patients with moderate-to-severe active rheumatoid arthritis confirmed equivalence of Nepexto to the reference product in terms of efficacy, safety and immunogenicity.

The CHMP positive opinion will now be considered by the European Commission (EC). Once approved, the EC will grant a centralized marketing authorization for member countries of the EU. The decision on the EC's approval is expected in May 2020.

Vinita Gupta, CEO, Lupin Limited said, "Biosimilars like Nepexto will play a critical role in expanding access to patients in Europe, providing an effective treatment for multiple therapies including rheumatoid arthritis. We are extremely pleased with the positive CHMP opinion on our application. This milestone brings us one step closer to bringing an affordable biosimilar to etanercept to the European market through our partner Mylan. Once approved by the European Commission, Nepexto will be our first biosimilar to receive regulatory approval in Europe. Building on this progress, we continue to focus on advancing our biosimilar pipeline."

Mylan President, Rajiv Malik commented, "We are pleased with the positive CHMP opinion for Nepexto, biosimilar etanercept. This recommendation validates the strong scientific program supporting this important treatment, which is one of 20 biosimilar products in our broad and diverse biosimilars portfolio, and our shared commitment with Lupin to help increase access to more affordable biologics treatments, such as etanercept, in Europe and many other regions around the world."

Enbrel had sales of approximately US$ 9.6 billion globally for the 12 months ending December 2019, according to IQVIA.

In June 2018, Lupin and Mylan announced a collaboration to commercialize a biosimilar to etanercept in several global markets.

Shares of LUPIN LTD. was last trading in BSE at Rs.547 as compared to the previous close of Rs. 558.15. The total number of shares traded during the day was 91814 in over 3314 trades.

The stock hit an intraday high of Rs. 593.2 and intraday low of 542.85. The net turnover during the day was Rs. 51762495.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

RPG Life Sciences Ltd Q4 net profit at Rs. 2.98 crore

Kirloskar Brothers Ltd Q4 consolidated net profit at Rs. 23 crore

Silver Lake and Co-Investors to invest additional Rs. 4,546.80 crore in Jio Platforms

Saurashtra Cement Ltd takes annual maintenance shutdown at Ranavav factory

TIMKEN India Ltd board recommends dividend of Rs. 50

RPG Life Sciences Q4'FY 20 revenue up by 29%

Infibeam Avenues announces Fourth Quarter and Fiscal Year 2020 Results

L&T reports consolidated earnings for Q4, FY2020

Refex Industries Limited board to finalize rights issue terms

Greaves accelerates performance in new business initiatives with 21% contribution in FY20

TIMKEN India Ltd Q4 PAT at Rs. 61.26 crore

Natural Capsules Ltd posts Rs. 0.11 crore in Q4 FY20

SMS Pharmaceuticals Ltd Q4 PAT drops to Rs. 6.32 crore

Sumitomo Chemical India Ltd Q4 consolidated PAT at Rs. 22.90 crore

L&T Board recommends Final Dividend of Rs. 8

Natural Capsules Ltd Board approves dividend of Rs. 0.60

Jyothy Labs Ltd Q4 FY20 consolidated PAT at Rs. 28.80 crore

Aditya Birla Capital Ltd reports consolidated Q4 PAT of Rs. 143.67 crore

PPAP Automotive Ltd reports consolidated PAT of Rs. 5.85 crore in Q4 FY20

CG-VAK Software & Exports Ltd Q4 consolidated PAT at Rs. 1.28 crore

Exide Industries Ltd reports lower top line in Q4 FY2020

Gateway Distriparks Ltd announces FY2020 performance

CG-VAK Software and Exports Ltd board recommends dividend of Rs. 0.75 for FY20

Infibeam Avenues Ltd to acquire Cardpay Technologies Pvt Ltd

Pfizer Ltd Board to consider FY20 results & Final Dividend on June 15, 2020

Sumitomo Chemical India Ltd board declares dividend of Rs. 0.55

IRB InvIT Fund board declares 4th distribution of Rs. 1.80 for FY2020

Apollo Pipes Ltd launches water storage tank

Gujarat Gas Ltd Q4 consolidated PAT at Rs. 250.46 crore

Dr. Kiran Mazumdar-Shaw from India named EY World Entrepreneur Of The Year™ 2020

Alkem Laboratories Ltd Board approves final dividend of Rs. 3

SBI - Q4 / FY2020 Highlights

Mahindra to plant a tree for every service availed digitally on its With You Hamesha app

V-Guard presents new range of AIKIDO air coolers to beat the heat

IndiGo operates flight chartered by NALSAR to transport 174 migrant workers

Maruti Suzuki sells over 1 lakh factory fitted CNG vehicles - Highest ever in a fiscal

Alkem Laboratories Ltd Q4FY20 consolidated PAT at Rs. 188.77 crore

Lasa Supergenerics Ltd Q4 FY2020 PAT at Rs. 2.58 crore

Saregama India Ltd Board recommends dividend of Rs. 1.50

SBI Q4 FY20 consolidated PAT at Rs. 6909.95 crore

Suven Life Sciences Ltd reports loss of Rs. 25.55 crore in Q4 FY20

Saregama India Ltd Q4 consolidated PAT at Rs. 15.81 crore

Snowman reports optimistic results in pessimistic market outlook backed by Strong Fundamentals and Robust Business Model

Zydus Cadila receives final approval from USFDA for Atazanavir Capsules

Cheviot Company Ltd Q4 PAT falls to Rs. 3.50 crore

JSW Steel Ltd allots 10,000 NCDs

Sun Pharma initiates Phase II clinical trial on AQCH, a phytopharmaceutical drug, as potential treatment for COVID-19 patients

Maruti Suzuki commissions 5 MW carport style photovoltaic solar power plant in Gurugram

Hexaware Technologies Ltd board to consider voluntary delisting on June 12, 2020, stock locked in upper circuit

TCS Wins 2020 SAP® Pinnacle Award







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019